8-KLeadership Changes

CVS HEALTH Corp 8-K Report, Executive Changes (Sep 13, 2022)

Filed September 13, 2022For Securities:CVS

Summary

CVS Health Corporation (CVS) announced a significant addition to its Board of Directors with the election of Jeffrey R. Balser, M.D., Ph.D., effective September 12, 2022. Dr. Balser brings extensive experience as President and CEO of Vanderbilt University Medical Center (VUMC) and Dean of Vanderbilt University School of Medicine. His leadership at VUMC has involved managing a large academic medical center, overseeing complex financial restructuring, and driving innovation in personalized medicine and health information technology. This appointment is investor-focused as Dr. Balser's deep expertise in healthcare delivery systems, financial management, risk oversight, and technological advancement aligns well with CVS Health's strategic objectives. His proven track record in leading organizational change and his clinical and research background are expected to provide valuable insights to the Board, particularly in areas related to medical affairs, which he will be joining.

Key Highlights

  • 1CVS Health has appointed Jeffrey R. Balser, M.D., Ph.D., to its Board of Directors.
  • 2Dr. Balser is the President and CEO of Vanderbilt University Medical Center and Dean of Vanderbilt University School of Medicine.
  • 3His experience includes leading a large academic medical center, financial restructuring, and acquisitions.
  • 4Dr. Balser has expertise in personalized medicine, pharmacogenomics, and health information technology.
  • 5He has been appointed to the Board's Medical Affairs Committee.
  • 6Dr. Balser has been deemed independent by the Board according to NYSE and company guidelines.
  • 7His compensation will align with that of other non-employee directors.

Frequently Asked Questions

Dr. Balser is a prominent figure in academic healthcare, currently serving as President and CEO of Vanderbilt University Medical Center and Dean of its School of Medicine. His appointment to the Board is significant due to his extensive experience in healthcare leadership, financial management of large health systems, strategic restructuring, and advancements in personalized medicine and health IT, which are all relevant to CVS Health's operations and future growth.

Dr. Balser brings a unique blend of clinical, research, and business leadership expertise. This includes experience in managing large regional health delivery systems, human capital management, hospital and practice acquisitions, risk management through quality and compliance oversight, and financial management (P&L and balance sheet). His background in pharmacogenomics and personalized medicine, along with his leadership in health information technology, are particularly valuable.

While an individual director's impact on strategy is usually collaborative, Dr. Balser's deep understanding of healthcare delivery, medical innovation, and financial stewardship is expected to provide valuable guidance to the Board's strategic decision-making. His appointment to the Medical Affairs Committee suggests a focus on areas directly related to the company's core health services and product development.

Dr. Balser's compensation for his service as a non-employee director will be consistent with that of other non-employee directors at CVS Health. This compensation will be prorated to reflect his commencement date of service on September 12, 2022, and is further detailed in the company's annual proxy statement.